News

New Virtual Mental Health and Substance Use (MHSU) Program From Compass Health Center Delivers Specialized Care to a Broader Audience, Bridging the Gap in Access to Essential Services

…

The post Compass Health Center Introduces Virtual Program to Improve Access to Mental Health and Substance Use Treatment for Young Adults and Adults first appeared on Enrose Magazine.

KANSAS CITY, Mo., June 15, 2023 (Newswire.com)
–
Dr. Irfan Handoo, a leading expert in psychiatry and renowned provider of transcranial magnetic stimulation (TMS) and IV ketamine treatments, is excited to announce the relocation of his clinic to a new state-of-the-art facility. The clinic has recently signed a lease and will move into a spacious 4,000-square-foot location at 7011 West 121st Street, Suite 105, Overland Park, KS 66209, on Monday, June 19.

This move marks a significant milestone for Dr. Handoo and his team as they continue their commitment to providing exceptional care and expanding access to cutting-edge treatments for patients struggling with mental health conditions. The new facility offers an environment designed to foster comfort and healing, providing a welcoming space for patients seeking TMS and IV ketamine treatments.

“We are thrilled to announce our upcoming move to Overland Park,” said Dr. Handoo. “This new clinic will allow us to serve our patients better, providing them with a modern and compassionate environment where they can continue to receive the high standards of care they have come to expect from us. Our goal is to create a nurturing space that complements the innovative treatments we offer, enabling our patients to find relief and improve their overall well-being.”

Deep TMS therapy, a noninvasive procedure that uses magnetic fields to stimulate targeted areas of the brain, has shown promising results in the treatment of treatment-resistant depression. IV ketamine treatments have also emerged as a breakthrough therapy for individuals who have not found relief from traditional treatments. Dr. Handoo’s expertise in administering these treatments, coupled with the new facility’s advanced capabilities, ensures that patients will receive the highest quality care in a comfortable and modern setting.

The new location boasts ample space for treatment rooms, cutting-edge equipment, and a welcoming reception area. Dr. Handoo and his team have meticulously designed the clinic to provide a serene and supportive atmosphere where patients can feel at ease throughout their treatment journey. The move to Overland Park represents a significant investment in the community and reaffirms Dr. Handoo’s commitment to improving mental health care in the region.

Patients seeking Deep TMS and IV ketamine treatments can schedule appointments at the new location starting Monday, June 19. Dr. Handoo and his team look forward to welcoming both existing and new patients to experience the enhanced care and comfort provided by the new clinic.

For more information about Dr. Irfan Handoo and his practice, please visit https://drhandoo.com/ or contact 816-441-9875.

Contact Information:

Dr. Irfan Handoo

[email protected]

816-441-9875

Original Source:

Kansas City’s Largest TMS and IV Ketamine Clinic Moving to Overland Park

The post Kansas City’s Largest TMS and IV Ketamine Clinic Moving to Overland Park first appeared on Enrose Magazine.

Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatment

DALLAS, June 15, 2023 (Newswire.com)
–
Nano Imrad Technology (NIT), an innovative medical research and development company, is pleased to announce the availability of Actinium-225 for medical research and treatment. Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatment.

With the capacity to produce significant quantities of Actinium-225 daily, NIT is not only making this precious element more accessible, but is also contributing significantly to the global fight against cancer.

Actinium-225, a radioactive element, is gaining recognition in the medical community for its potential in targeted alpha therapy for cancer treatment. Its ability to deliver precise radiation directly to cancer cells, while leaving healthy tissue unaffected, has shown promise in shrinking and even eliminating tumors.

NIT has developed a breakthrough method to produce Actinium-225 in a reliable, safe, and cost-effective manner, overcoming traditional challenges associated with the production and acquisition of this element. This pioneering approach enhances access to Actinium-225, empowering researchers, clinicians, and patients to benefit from cutting-edge treatments and technologies.

NIT’s Actinium-225 will be available to licensed researchers, research institutions, and clinicians, who can utilize this crucial element for research and treatments. Actinium-225 is available only to organizations and individuals with a verified Radioactive Materials (RAM) License.

For more information about NIT and Actinium-225, please visit https://nitresearch.com.

About Nano Imrad Technology (NIT)

NIT is a medical research and development company specializing in the production of diagnostic imaging and therapeutic medical isotopes. Their core technology focuses on immune-labeled radionuclide nanoparticles, and their mission is to make Actinium-225 widely available for research and treatment purposes, revolutionizing the landscape of cancer treatment.

Contact Information:

Ed O’Connor

Director of Sales

[email protected]

+1 (332) 213-9516

Original Source:

Nano Imrad Technology (NIT) Announces Availability of Actinium-225, Pioneering a New Era of Cancer Treatment

The post Nano Imrad Technology (NIT) Announces Availability of Actinium-225, Pioneering a New Era of Cancer Treatment first appeared on Enrose Magazine.